PlainPharmaWatch

CMS Open Payments · Program Year 2024

Alnylam Pharmaceuticals Inc.

Alnylam Pharmaceuticals Inc. reported $39,181,235.63 in payments to 19,104 physicians and teaching hospitals across 36,687 transactions.

See the rankings → How this is sourced
$39.2M
Total payments
36,687
Transactions
19,104
Recipients
+$457.7K
General Payments vs PY2023

Alnylam Pharmaceuticals Inc. reported $39,181,235.63 in payments to 19,104 physicians and teaching hospitals in CMS Open Payments Program Year 2024 - ranking #58 of 1,925 reporting manufacturers (0.3% of all US industry payments), averaging $2.1K per recipient across 7 payment categories. Figures are company-reported under the Physician Payments Sunshine Act; a reported payment is a financial relationship, not evidence of wrongdoing.

Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.

Compiled from official public sources by the editorial team.

The verdict

Alnylam Pharmaceuticals Inc. pairs top-5% payment volume with a broadly spread payment pattern across many recipients.

#58
of 1,925 companies
0.3%
of all US industry payments
0.2%
paid to its single top recipient
7
payment categories

Release-over-release change

General Payments changed from PY2023 to PY2024

Alnylam Pharmaceuticals Inc.'s CMS-reported General Payments increased by $457.7K (+7.6%) from PY2023 to PY2024. The comparison uses the same CMS manufacturer-by-payment-category summary for both years and excludes research and ownership or investment records.

CMS source labels for this exact identifier: PY2022: ALNYLAM PHARMACEUTICALS INC.PY2023: ALNYLAM PHARMACEUTICALS INC.PY2024: Alnylam Pharmaceuticals Inc.. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.

Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.

General Payments: PY2023 vs PY2024

Annual CMS-reported totals for this company, not an all-category Open Payments total

PY2023$6.0MPY2024$6.5M
PY2023
$6,047,708.24
PY2024
$6,505,436.41

How Alnylam Pharmaceuticals Inc. ranks nationally

Where this company's total reported payments fall within the full national distribution of all 1,925 companies in CMS Open Payments, not just its nearest peers.

Alnylam Pharmaceuticals Inc.'s total vs. every reporting company

CMS Open Payments, Program Year 2024

$39,181,236 Top 3% higher than 97% of 1,925 reporting companies

$9–$28: 3 reporting companies (0%). Below this entry. $28–$87: 10 reporting companies (1%). Below this entry. $87–$270: 20 reporting companies (1%). Below this entry. $270–$838: 41 reporting companies (2%). Below this entry. $838–$2,603: 76 reporting companies (4%). Below this entry. $2,603–$8,084: 114 reporting companies (6%). Below this entry. $8,084–$25,112: 167 reporting companies (9%). Below this entry. $25,112–$78,003: 249 reporting companies (13%). Below this entry. $78,003–$242,294: 295 reporting companies (15%). Below this entry. $242,294–$752,621: 270 reporting companies (14%). Below this entry. $752,621–$2,337,813: 263 reporting companies (14%). Below this entry. $2,337,813–$7,261,783: 200 reporting companies (10%). Below this entry. $7,261,783–$22,556,757: 133 reporting companies (7%). Below this entry. $22,556,757–$70,066,439: 45 reporting companies (2%). This entry sits in this band. $70,066,439–$217,642,369: 26 reporting companies (1%). Above this entry. $217,642,369–$676,046,922: 13 reporting companies (1%). Above this entry. This company $9 $676,046,922 every reporting company, bucketed by value

Each bar is a progressively wider band; taller bars hold more reporting companies. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source CMS Open Payments · 2024

What the Data Shows for Alnylam Pharmaceuticals Inc.

Averaging $1.1K per transaction and $2.1K per recipient, Alnylam Pharmaceuticals Inc.'s Program Year 2024 total comes to $39,181,235.63 across 36,687 transactions and 19,104 physicians and teaching hospitals. In the CMS Open Payments database that is good for rank #58 of 1,925 companies, representing 0.3% of all industry payments reported nationwide for the year.

231 transactions worth $2.9M make "Consulting Fee" the top general-payment category in the 7-category breakdown below, 7.4% of the reported total (see our methodology for how research and ownership payments are reported separately).

General Payment Breakdown by Type

Across 7 types of general payments, Alnylam Pharmaceuticals Inc.'s largest category was "Consulting Fee" at $2.9M - 7.4% of the company's reported total.

How Alnylam Pharmaceuticals Inc. divides its payments

Ranked by total dollars reported per category

1. Consulting Fee$2.9M2. Compensation for Services…$2.2M3. Food and Beverage$550.5K4. Space Rental or Facility …$421.6K5. Travel and Lodging$333.9K6. Grant$70.8K7. Education$598.48
Payment Type Amount Transactions
Consulting Fee $2.9M 231
Compensation for Services Other Than Consulting $2.2M 419
Food and Beverage $550.5K 17,454
Space Rental or Facility Fees $421.6K 104
Travel and Lodging $333.9K 875
Grant $70.8K 9
Education $598.48 12

Recipient Concentration in General Payments

The five largest recipient relationships account for $2,782,449.53 (42.8%) of $6,505,436.41 in this company's General Payments records across 9,834 recipients. This is a CMS Open Payments Program Year 2024 General Payments view only: it excludes research and ownership/investment records, so it is not the all-category company total above.

Largest General-Payment relationships for Alnylam Pharmaceuticals Inc.

The five named recipients with the highest reported General Payments from this company

Brigham And Womens Hospital$1.1MSushama Scalera$488.9KDennis Ausiello$484.6KMargaret A Hamburg$476.9KArthur Decillis$281.3K
  1. 1

    Brigham And Womens Hospital

    $1,050,759.48 across 6 reported transactions

  2. 2

    Sushama Scalera

    $488,887.50 across 10 reported transactions

  3. 3

    Dennis Ausiello

    $484,629.86 across 15 reported transactions

  4. 4

    Margaret A Hamburg

    $476,884.99 across 18 reported transactions

  5. 5

    Arthur Decillis

    $281,287.70 across 12 reported transactions

Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.

Payment Size Analysis

Average transaction size: $1.1K. Average per recipient: $2.1K.

Total Amount

$39,181,235.63

Avg per Transaction

$1.1K

Avg per Recipient

$2.1K

Payment Transparency Context

What is the Sunshine Act?

The Physician Payments Sunshine Act (part of the Affordable Care Act) requires pharmaceutical and medical device manufacturers to report payments and transfers of value to physicians and teaching hospitals. These payments can include consulting fees, research grants, speaker fees, food and beverages, travel, royalties, and other forms of compensation.

Industry Total (2024)

$13.9B

across 1,925 companies

Alnylam Pharmaceuticals Inc. Share

0.3%

#58 by total payments

Companies with Similar Payment Volumes

Pharmaceutical companies with payment totals similar to Alnylam Pharmaceuticals Inc.

ViiV Healthcare Company

$38.7M 65,891 recipients

Spinal Simplicity, LLC

$40.8M 4,988 recipients

Boehringer Ingelheim International GmbH

$41.1M 2,203 recipients

Exelixis Inc.

$37.1M 10,612 recipients

Sanofi Pasteur Inc.

$42.5M 14,446 recipients

Alexion Pharmaceuticals, Inc.

$34.7M 48,499 recipients

Frequently Asked Questions

How much did Alnylam Pharmaceuticals Inc. pay to physicians and hospitals in 2024? ▾
Alnylam Pharmaceuticals Inc. made $39,181,235.63 in payments to physicians and hospitals in Program Year 2024, across 36,687 individual transactions. This represents 0.3% of all industry payments reported to CMS Open Payments.
How many physicians received payments from Alnylam Pharmaceuticals Inc.? ▾
Averaging $2.1K per recipient, Alnylam Pharmaceuticals Inc.'s 2024 payments reached 19,104 physicians and teaching hospitals.
What types of payments did Alnylam Pharmaceuticals Inc. make? ▾
General payments from Alnylam Pharmaceuticals Inc. span 7 distinct categories, covering things like consulting, meals, and travel. The largest general-payment category was "Consulting Fee" at $2.9M, representing 7.4% of the company's reported total.
How does Alnylam Pharmaceuticals Inc. rank among pharmaceutical companies? ▾
Out of 1,925 companies in the CMS Open Payments database for 2024, Alnylam Pharmaceuticals Inc. ranks #58 by total payment amount.
What is the average payment size from Alnylam Pharmaceuticals Inc.? ▾
Alnylam Pharmaceuticals Inc.'s 36,687 transactions to 19,104 recipients in 2024 averaged $1.1K per transaction.
Where does the payment data for Alnylam Pharmaceuticals Inc. come from? ▾
This data comes from the CMS Open Payments program (Sunshine Act), which requires pharmaceutical and medical device companies to report payments and transfers of value to physicians and teaching hospitals. The data covers Program Year 2024.

Data Source: Centers for Medicare & Medicaid Services (CMS) Open Payments, Program Year 2024. Data includes general payments, research payments, and physician ownership/investment interests as required by the Physician Payments Sunshine Act. Total industry payments: $13.9B across 1,925 companies.

Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch Editorial
Disclaimer

This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

View saved (companies)
Download Alnylam Pharmaceuticals Inc.'s data (CSV)
Embed this widget

Copy this snippet to embed a live-linked card on your own site.

Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-25.